BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tokunaga Y, Sasaki H, Saito T. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. Surgery. 2007;141:346-353. [PMID: 17349846 DOI: 10.1016/j.surg.2006.06.025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ. Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit Rev Oncol Hematol. 2011;79:224-250. [PMID: 20719530 DOI: 10.1016/j.critrevonc.2010.07.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
2 Ochiai T, Umeki M, Miyake H, Iida T, Okumura M, Ohno K, Sakamoto M, Miyoshi N, Takahashi M, Tsumura H, Tokunaga Y, Naitou H, Fukui T. Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. Oncol Rep 2014;32:887-92. [PMID: 24994673 DOI: 10.3892/or.2014.3299] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
3 Koopman M, Venderbosch S, van Tinteren H, Ligtenberg MJ, Nagtegaal I, Van Krieken JH, Punt CJ. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer. 2009;45:1999-2006. [PMID: 19457654 DOI: 10.1016/j.ejca.2009.04.017] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
4 Crea F, Nobili S, Paolicchi E, Perrone G, Napoli C, Landini I, Danesi R, Mini E. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updat. 2011;14:280-296. [PMID: 21955833 DOI: 10.1016/j.drup.2011.08.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 7.4] [Reference Citation Analysis]
5 Kugimiya N, Harada E, Suehiro Y, Suga A, Takemoto Y, Hamano K. Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines. Oncol Lett 2019;17:5267-74. [PMID: 31186743 DOI: 10.3892/ol.2019.10181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Quidde J, Arnold D, Stein A. Clinical management of localized colon cancer with capecitabine. Clin Med Insights Oncol 2012;6:363-73. [PMID: 23170068 DOI: 10.4137/CMO.S8194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Shigeta K, Ishii Y, Hasegawa H, Okabayashi K, Kitagawa Y. Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis. World J Surg 2014;38:3248-56. [PMID: 25167895 DOI: 10.1007/s00268-014-2738-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
8 Mohelnikova-Duchonova B, Melichar B, Soucek P. FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World J Gastroenterol 2014; 20(30): 10316-10330 [PMID: 25132748 DOI: 10.3748/wjg.v20.i30.10316] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
9 Sun X, Guo S. The Prognostic and Predictive Value of Dihydropyrimidine Dehydrogenase-Related Indicators in Clinical Outcomes of Chemotherapy in Colorectal Cancer Patients: a Systematic Review and Meta-Analysis. Pathol Oncol Res 2020;26:121-31. [PMID: 30519982 DOI: 10.1007/s12253-018-00563-3] [Reference Citation Analysis]
10 Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:57-84. [PMID: 26753006 DOI: 10.1177/1758834015614530] [Cited by in Crossref: 203] [Cited by in F6Publishing: 194] [Article Influence: 40.6] [Reference Citation Analysis]
11 Karasawa H, Miura K, Fujibuchi W, Ishida K, Kaneko N, Kinouchi M, Okabe M, Ando T, Murata Y, Sasaki H, Takami K, Yamamura A, Shibata C, Sasaki I. Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci 2009;100:903-13. [PMID: 19302291 DOI: 10.1111/j.1349-7006.2009.01112.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
12 Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S. 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011;12:251-265. [PMID: 21332317 DOI: 10.2217/pgs.10.167] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
13 Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? European Journal of Cancer 2009;45:1935-49. [DOI: 10.1016/j.ejca.2009.04.023] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 5.7] [Reference Citation Analysis]
14 Kataoka K, Kanazawa A, Nakajima A, Yamaguchi A, Arimoto A. Prognostic value of biomarkers in metastatic colorectal cancer patients. J Surg Res 2015;194:343-50. [PMID: 25456112 DOI: 10.1016/j.jss.2014.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
15 Gajjar KK, Vora HH, Kobawala TP, Trivedi TI, Ghosh NR. Deciphering the potential value of 5-fluorouracil metabolic enzymes in predicting prognosis and treatment response of colorectal cancer patients. Int J Biol Markers 2018;33:180-8. [DOI: 10.1177/1724600817748539] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
16 Izuishi K, Haba R, Kushida Y, Kadota K, Takebayashi R, Sano T, Usuki H, Hossain MA, Mori H, Masaki T, Suzuki Y. S-1 and the treatment of gastric cancer with peritoneal dissemination. Exp Ther Med 2011;2:985-90. [PMID: 22977609 DOI: 10.3892/etm.2011.290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
17 Fariña-Sarasqueta A, van Lijnschoten G, Rutten HJ, van den Brule AJ. Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study. Cancer Chemother Pharmacol 2010;66:1167-71. [PMID: 20665215 DOI: 10.1007/s00280-010-1403-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
18 Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Ohge H, Sueda T. Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection. J Surg Oncol. 2011;104:146-154. [PMID: 21538357 DOI: 10.1002/jso.21955] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
19 Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol 2014; 20(29): 9775-9827 [PMID: 25110414 DOI: 10.3748/wjg.v20.i29.9775] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 75] [Article Influence: 10.6] [Reference Citation Analysis]
20 Santos C, Vilar E, Capella G, Salazar R. Molecular markers in colorectal cancer: clinical relevance in stage II colon cancer. Colorectal Cancer 2013;2:243-63. [DOI: 10.2217/crc.13.24] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Komori S, Osada S, Tomita H, Nishio K, Kumazawa I, Tachibana S, Tsuchiya J, Yoshida K. Predictive value of orotate phosphoribosyltransferase in colorectal cancer patients receiving 5-FU-based chemotherapy. Mol Clin Oncol 2013;1:453-60. [PMID: 24649191 DOI: 10.3892/mco.2013.71] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
22 Schwarzenbach H. Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy. EPMA J 2010;1:485-94. [PMID: 23199090 DOI: 10.1007/s13167-010-0022-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Kato Y, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Hiyama E, Sueda T. Impact of intratumoral thymidylate synthase expression on prognosis after surgical resection for ampullary carcinoma: Impact of TS in Ampullary Carcinoma. J Surg Oncol 2011;103:663-8. [DOI: 10.1002/jso.21879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]